Bentsi Algazi Appointed VP of Operations of Sorrel Medical

Bentsi Algazi as Vice President of Operations to meet growing interest in its award-winning wearable self-injection devices.

As VP Operations, Bentsi Algazi will oversee all of Sorrel’s supply chain, engineering, production and vendor management activities. He brings over 20 years’ managerial experience in R&D, operations, procurement and production management in both high-tech and medical device markets, with a proven history of success in implementing customized innovative management and business solutions.

“Sorrel’s proprietary wearable drug delivery platform is receiving considerable attention from leading pharmaceutical and biotech companies amid growing demand for patient-friendly and partner-focused solutions,” said Andrei Yosef, PhD, CEO for Sorrel Medical. “As Sorrel progresses from R&D to manufacturing, we continue to invest in our Operations team. We are delighted to welcome Bentsi to Sorrel, where his extensive experience in operations and supply chain management will prove integral to expediting our production capabilities.”

Bentsi Algazi joins Sorrel from Juganu Ltd., a leader in smart lighting, networking and sensing solutions for municipal and commercial markets, where he served as Chief Operations Officer. Prior to Juganu, he was Micro-Infusion R&D Site Manager at West Pharmaceutical Services, Inc., leading the team responsible for bringing the company’s SmartDose® wearable injector to commercialization. Before joining West, Bentsi served as COO at PowerPaper, a developer of micro-electric solutions for cosmetic & RFID applications.

“Sorrel Medical is emerging as a key player in the wearable injector and connected drug delivery space, bringing innovative solutions for the safe and efficient self-administration of new biologic medications,” said Bentsi Algazi. “I am excited to join Sorrel’s dynamic team with a culture of excellence committed to working with pharmaceutical partners to enhance the self-administration experience for potentially millions of patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version